NHE3-IN-2 is primarily researched for its potential therapeutic applications in treating conditions related to sodium-hydrogen exchange. It is being studied for its role in managing hypertension and heart failure by inhibiting the sodium-hydrogen exchanger isoform 3 (NHE3), which plays a key role in sodium absorption in the kidneys and intestines. By blocking NHE3, it may help reduce sodium retention, thereby lowering blood pressure and alleviating fluid overload in patients with heart failure. Additionally, it is being explored for its potential benefits in treating metabolic acidosis and certain gastrointestinal disorders where sodium balance is disrupted. Research is ongoing to further understand its efficacy and safety in clinical settings.